Coronary artery disease: a dam in the river for ranolazine

Affiliations

¹ Department of Cardiothoracic Surgery, Erasmus University Medical Center, 3000 CA, Rotterdam, Netherlands. Electronic address: s.head@erasmusmc.nl.
² Department of Cardiothoracic Surgery, Erasmus University Medical Center, 3000 CA, Rotterdam, Netherlands.

Comment

Stuart J Head et al. Lancet. 2016.

. 2016 Jan 9;387(10014):100-2.

doi: 10.1016/S0140-6736(15)00458-4. Epub 2015 Oct 22.

¹ Department of Cardiothoracic Surgery, Erasmus University Medical Center, 3000 CA, Rotterdam, Netherlands. Electronic address: s.head@erasmusmc.nl.
² Department of Cardiothoracic Surgery, Erasmus University Medical Center, 3000 CA, Rotterdam, Netherlands.

No abstract available

Comment on

Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.
Weisz G, Généreux P, Iñiguez A, Zurakowski A, Shechter M, Alexander KP, Dressler O, Osmukhina A, James S, Ohman EM, Ben-Yehuda O, Farzaneh-Far R, Stone GW; RIVER-PCI investigators. Weisz G, et al. Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22. Lancet. 2016. PMID: 26474810 Clinical Trial.